2021
PD-L1 (Programmed Death Ligand 1) Regulates T-Cell Differentiation to Control Adaptive Venous Remodeling
Matsubara Y, Gonzalez L, Kiwan G, Liu J, Langford J, Gao M, Gao X, Taniguchi R, Yatsula B, Furuyama T, Matsumoto T, Komori K, Mori M, Dardik A. PD-L1 (Programmed Death Ligand 1) Regulates T-Cell Differentiation to Control Adaptive Venous Remodeling. Arteriosclerosis Thrombosis And Vascular Biology 2021, 41: 2909-2922. PMID: 34670406, PMCID: PMC8664128, DOI: 10.1161/atvbaha.121.316380.Peer-Reviewed Original ResearchConceptsPD-L1AVF maturationPD-L1 activityVenous remodelingT cellsL1 antibodyArteriovenous fistulaNude miceMouse aortocaval fistula modelEnd-stage renal diseaseT helper type 2 cellsT helper type 1 (Th1) cellsPrimary success rateSmooth muscle cell proliferationRegulatory T cellsT cell activityT-cell transferAortocaval fistula modelPreferred vascular accessVascular wall thickeningM1-type macrophagesM2-type macrophagesPotential therapeutic targetMuscle cell proliferationType 1 cellsInhibition of T-Cells by Cyclosporine A Reduces Macrophage Accumulation to Regulate Venous Adaptive Remodeling and Increase Arteriovenous Fistula Maturation
Matsubara Y, Kiwan G, Liu J, Gonzalez L, Langford J, Gao M, Gao X, Taniguchi R, Yatsula B, Furuyama T, Matsumoto T, Komori K, Dardik A. Inhibition of T-Cells by Cyclosporine A Reduces Macrophage Accumulation to Regulate Venous Adaptive Remodeling and Increase Arteriovenous Fistula Maturation. Arteriosclerosis Thrombosis And Vascular Biology 2021, 41: e160-e174. PMID: 33472405, PMCID: PMC7904667, DOI: 10.1161/atvbaha.120.315875.Peer-Reviewed Original ResearchConceptsVascular wall thickeningT helper type 1 (Th1) cellsSuccessful AVF maturationAVF maturationRegulatory T cellsMacrophage accumulationT cellsType 1 cellsArteriovenous fistulaVenous remodelingWall thickeningMouse aortocaval fistula modelT helper type 2T helper type 2 cellsAdaptive remodelingM2 macrophage accumulationPrimary success rateAortocaval fistula modelArteriovenous fistula maturationPreferred vascular accessAnti-inflammatory macrophagesT cell functionWild-type miceEffect of CsAType 2 cells
2020
Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease
Kim TI, Kiwan G, Mohamedali A, Zhang Y, Mena-Hurtado C, Mojibian H, Guzman RJ, Ochoa Chaar CI. Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease. Journal Of Vascular Surgery 2020, 73: 911-917. PMID: 33038480, DOI: 10.1016/j.jvs.2020.08.146.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmputation, SurgicalCardiovascular AgentsCoated Materials, BiocompatibleDrug-Eluting StentsEndovascular ProceduresFemaleHumansLimb SalvageMaleMiddle AgedPaclitaxelPeripheral Arterial DiseaseProsthesis DesignRetreatmentRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeVascular PatencyConceptsPaclitaxel-coated devicesPeripheral artery diseaseCause of mortalityPCD useRisk of mortalityCumulative doseFemoropopliteal peripheral artery diseaseKaplan-Meier survival curvesLong-term mortalityPeripheral arterial diseaseCox regression analysisDrug-coated balloonsOutcome of treatmentDrug-eluting stentsMajor amputationPrimary patencyReintervention rateArtery diseaseArterial diseaseRandomized trialsOpen surgeryPresent studySingle institutionEndovascular interventionPatients